Why Women from Africa and South Asia Are Choosing India for Cervical Cancer Treatment

Brachytherapy. Robotic surgery. Bevacizumab. Pembrolizumab. These are the treatments that cure and control cervical cancer — and they are unavailable or unaffordable for most women in sub-Saharan Africa and much of South Asia. This guide explains why India's top cancer centres have become the practical answer for patients from Nigeria, Ghana, Kenya, Tanzania, Zambia, and Bangladesh.

By Gaf Healthcare Editorial Team

2026-05-10

<!DOCTYPE html> <html lang="en"> <head> <meta charset="UTF-8"> <meta name="viewport" content="width=device-width, initial-scale=1.0"> <title>Why Women from Africa and South Asia Are Choosing India for Cervical Cancer Treatment</title> <meta name="description" content="World-class cervical cancer care at 80–90% less than US costs. See why patients from Nigeria, Kenya, Ghana, UAE and beyond choose India's top cancer centres."> <link rel="preconnect" href="https://fonts.googleapis.com"> <link href="https://fonts.googleapis.com/css2?family=Lora:ital,wght@0,400;0,600;1,400&family=Source+Sans+3:wght@400;500;600&display=swap" rel="stylesheet"> <style> , ::before, *::after { box-sizing: border-box; margin: 0; padding: 0; }

:root { --cream: #F5F2EB; --cream-dark: #EDE9DF; --green-dark: #1B5E3B; --green-mid: #2D7A52; --green-light: #EAF4EE; --green-border: #C2DFCC; --red-accent: #B84040; --red-bg: #FDF2F2; --amber: #B07A15; --amber-bg: #FDF7EC; --amber-border: #E8D5A0; --text-primary: #1A1A18; --text-body: #2E2E2A; --text-muted: #6B6860; --text-green: #1B5E3B; --border-soft: #DDD9CF; }

body { font-family: 'Source Sans 3', sans-serif; background-color: var(--cream); color: var(--text-body); font-size: 18px; line-height: 1.75; -webkit-font-smoothing: antialiased; }

.page-wrap { max-width: 740px; margin: 0 auto; padding: 48px 24px 80px; }

.meta-tag { display: inline-block; font-size: 11px; font-weight: 600; letter-spacing: 0.12em; text-transform: uppercase; color: var(--text-green); background: var(--green-light); border: 1px solid var(--green-border); border-radius: 4px; padding: 3px 10px; margin-bottom: 18px; }

h1 { font-family: 'Lora', Georgia, serif; font-size: clamp(26px, 4vw, 38px); font-weight: 600; line-height: 1.25; color: var(--text-primary); margin-bottom: 18px; letter-spacing: -0.01em; }

.deck { font-size: 19px; line-height: 1.6; color: var(--text-muted); margin-bottom: 28px; border-bottom: 1px solid var(--border-soft); padding-bottom: 28px; }

/ ILLUSTRATION / .illustration-wrap { margin: 8px 0 36px; border-radius: 10px; overflow: hidden; border: 1px solid var(--border-soft); background: var(--cream-dark); } .illustration-wrap svg { display: block; width: 100%; } .img-caption { font-size: 13px; color: var(--text-muted); padding: 10px 16px 12px; border-top: 1px solid var(--border-soft); font-style: italic; line-height: 1.6; }

/ TOC / .toc-box { background: var(--cream-dark); border: 1px solid var(--border-soft); border-radius: 10px; padding: 20px 24px 24px; margin: 0 0 40px; } .toc-label { display: flex; align-items: center; gap: 8px; font-size: 11px; font-weight: 600; letter-spacing: 0.1em; text-transform: uppercase; color: var(--text-muted); margin-bottom: 14px; } .toc-label::before { content: ""; display: inline-block; width: 14px; height: 14px; background: var(--border-soft); border-radius: 2px; } .toc-box ol { list-style: none; padding: 0; display: flex; flex-direction: column; gap: 8px; } .toc-box ol li a { color: var(--text-green); text-decoration: none; font-size: 16px; font-weight: 500; border-bottom: 1px solid transparent; transition: border-color 0.15s; } .toc-box ol li a:hover { border-color: var(--green-mid); }

/ PROSE / .prose h2 { font-family: 'Lora', Georgia, serif; font-size: clamp(20px, 3vw, 26px); font-weight: 600; color: var(--text-primary); margin: 44px 0 6px; padding-bottom: 12px; border-bottom: 1px solid var(--border-soft); letter-spacing: -0.01em; }

.prose p { font-family: 'Lora', Georgia, serif; font-size: 18px; line-height: 1.82; color: var(--text-body); margin-bottom: 16px; max-width: 68ch; } .prose p strong { font-weight: 600; color: var(--text-primary); } .prose p.impact { font-size: 19px; font-style: italic; color: var(--text-muted); border-left: 3px solid var(--green-mid); padding-left: 18px; margin: 24px 0; }

/ QUICK ANSWER / .quick-box { background: var(--green-light); border: 1.5px solid var(--green-border); border-radius: 10px; padding: 20px 24px 22px; margin: 20px 0 24px; } .quick-box .qa-label { font-size: 11px; font-weight: 600; letter-spacing: 0.1em; text-transform: uppercase; color: var(--amber); display: flex; align-items: center; gap: 6px; margin-bottom: 10px; } .quick-box .qa-label::before { content: "⚡"; font-size: 13px; } .quick-box .qa-question { font-family: 'Source Sans 3', sans-serif; font-weight: 600; font-size: 17px; color: var(--text-primary); margin-bottom: 10px; } .quick-box .qa-answer { font-family: 'Source Sans 3', sans-serif; font-size: 16px; line-height: 1.7; color: var(--text-body); } .quick-box .qa-answer strong { color: var(--text-primary); }

/ STAT STRIP / .stat-strip { display: grid; grid-template-columns: repeat(auto-fit, minmax(120px, 1fr)); border: 1px solid var(--border-soft); border-radius: 8px; overflow: hidden; margin: 18px 0 24px; } .stat-cell { padding: 14px 16px 16px; border-right: 1px solid var(--border-soft); } .stat-cell:last-child { border-right: none; } .stat-cell .stat-label { font-size: 10px; font-weight: 600; letter-spacing: 0.1em; text-transform: uppercase; color: var(--text-muted); margin-bottom: 5px; } .stat-cell .stat-val { font-size: 22px; font-weight: 600; color: var(--green-mid); font-family: 'Source Sans 3', sans-serif; line-height: 1.1; }

/ REASON CARDS / .reason-list { display: flex; flex-direction: column; gap: 16px; margin: 20px 0 28px; } .reason-card { display: flex; gap: 18px; align-items: flex-start; background: #fff; border: 1px solid var(--border-soft); border-radius: 10px; padding: 18px 20px 20px; } .reason-number { font-family: 'Lora', Georgia, serif; font-size: 28px; font-weight: 600; color: var(--green-border); line-height: 1; flex-shrink: 0; min-width: 32px; padding-top: 2px; } .reason-body h4 { font-family: 'Source Sans 3', sans-serif; font-size: 16px; font-weight: 600; color: var(--text-primary); margin-bottom: 6px; } .reason-body p { font-family: 'Source Sans 3', sans-serif; font-size: 15px; color: var(--text-muted); line-height: 1.65; margin: 0; max-width: none; } .reason-body p strong { color: var(--text-primary); }

/ COUNTRY CARDS / .country-grid { display: grid; grid-template-columns: 1fr 1fr; gap: 14px; margin: 20px 0 28px; } .country-card { background: #fff; border: 1px solid var(--border-soft); border-radius: 10px; padding: 16px 18px 18px; } .country-card .country-name { font-family: 'Source Sans 3', sans-serif; font-size: 15px; font-weight: 600; color: var(--text-primary); margin-bottom: 8px; display: flex; align-items: center; gap: 8px; } .country-card .country-flag { font-size: 18px; } .country-card ul { list-style: none; padding: 0; display: flex; flex-direction: column; gap: 5px; } .country-card ul li { font-family: 'Source Sans 3', sans-serif; font-size: 13px; color: var(--text-muted); padding-left: 14px; position: relative; line-height: 1.5; } .country-card ul li::before { content: "·"; position: absolute; left: 0; font-weight: 700; } .country-card ul li strong { color: var(--text-primary); font-weight: 600; }

/ COST TABLE / .cost-table { width: 100%; border-collapse: collapse; border: 1px solid var(--border-soft); border-radius: 8px; overflow: hidden; margin: 18px 0 8px; font-size: 14px; } .cost-table thead th { background: var(--cream-dark); padding: 11px 14px; text-align: left; font-size: 10px; font-weight: 600; letter-spacing: 0.07em; text-transform: uppercase; color: var(--text-muted); border-bottom: 1px solid var(--border-soft); } .cost-table thead th.india-head { background: var(--green-light); color: var(--green-dark); } .cost-table tbody td { padding: 11px 14px; border-bottom: 1px solid var(--border-soft); font-family: 'Source Sans 3', sans-serif; color: var(--text-body); line-height: 1.5; vertical-align: top; } .cost-table tbody tr:last-child td { border-bottom: none; } .cost-table tbody td:first-child { font-weight: 600; color: var(--text-primary); width: 35%; } .cost-table .highlight td { background: #FAFAF7; } .cost-table .saving { color: var(--green-mid); font-weight: 600; }

/ TIMELINE / .timeline { display: flex; flex-direction: column; gap: 0; margin: 20px 0 28px; } .timeline-item { display: flex; gap: 18px; align-items: flex-start; } .timeline-left { display: flex; flex-direction: column; align-items: center; flex-shrink: 0; width: 40px; } .timeline-dot { width: 36px; height: 36px; border-radius: 50%; background: var(--green-dark); display: flex; align-items: center; justify-content: center; font-family: 'Source Sans 3', sans-serif; font-size: 14px; font-weight: 600; color: #fff; flex-shrink: 0; } .timeline-line { width: 2px; background: var(--green-border); flex: 1; min-height: 24px; } .timeline-item:last-child .timeline-line { display: none; } .timeline-content { padding: 4px 0 28px; } .timeline-content h4 { font-family: 'Source Sans 3', sans-serif; font-size: 16px; font-weight: 600; color: var(--text-primary); margin-bottom: 4px; } .timeline-content p { font-family: 'Source Sans 3', sans-serif; font-size: 15px; color: var(--text-muted); line-height: 1.65; margin: 0; max-width: none; } .timeline-content p strong { color: var(--text-primary); }

/ HOSPITAL CARDS / .hospital-grid { display: flex; flex-direction: column; gap: 12px; margin: 20px 0 28px; } .hospital-card { border: 1px solid var(--border-soft); border-radius: 10px; padding: 16px 20px 18px; background: #fff; display: flex; gap: 16px; align-items: flex-start; } .hospital-rank { font-family: 'Source Sans 3', sans-serif; font-size: 22px; font-weight: 600; color: var(--green-border); line-height: 1; flex-shrink: 0; min-width: 28px; padding-top: 2px; } .hospital-info h4 { font-family: 'Source Sans 3', sans-serif; font-size: 16px; font-weight: 600; color: var(--text-primary); margin-bottom: 4px; } .hospital-info h4 a { color: var(--text-primary); text-decoration: none; border-bottom: 1px solid var(--green-border); transition: border-color 0.15s; } .hospital-info h4 a:hover { border-color: var(--green-mid); } .hospital-info p { font-family: 'Source Sans 3', sans-serif; font-size: 14px; color: var(--text-muted); line-height: 1.6; margin: 0; max-width: none; } .hospital-info p strong { color: var(--text-primary); font-weight: 600; }

/ CALLOUTS / .callout-red { border-left: 3px solid var(--red-accent); background: var(--red-bg); border-radius: 0 8px 8px 0; padding: 16px 20px 18px; margin: 20px 0; } .callout-red .callout-label { font-size: 11px; font-weight: 600; letter-spacing: 0.1em; text-transform: uppercase; color: var(--red-accent); margin-bottom: 8px; } .callout-green { border-left: 3px solid var(--green-mid); background: var(--green-light); border-radius: 0 8px 8px 0; padding: 16px 20px 18px; margin: 20px 0; } .callout-green .callout-label { font-size: 11px; font-weight: 600; letter-spacing: 0.1em; text-transform: uppercase; color: var(--text-green); margin-bottom: 8px; } .callout-amber { border-left: 3px solid var(--amber); background: var(--amber-bg); border-radius: 0 8px 8px 0; padding: 16px 20px 18px; margin: 20px 0; } .callout-amber .callout-label { font-size: 11px; font-weight: 600; letter-spacing: 0.1em; text-transform: uppercase; color: var(--amber); margin-bottom: 8px; } .callout-red p, .callout-green p, .callout-amber p { font-size: 16px; line-height: 1.7; font-family: 'Source Sans 3', sans-serif; color: var(--text-body); margin: 0; max-width: none; }

.sources-line { font-size: 13px; color: var(--text-muted); margin: 4px 0 24px; font-style: italic; }

/ CTAs / .cta-a { background: var(--green-dark); border-radius: 12px; padding: 28px 28px 30px; margin: 32px 0; } .cta-a .cta-h { font-family: 'Source Sans 3', sans-serif; font-size: 18px; font-weight: 600; color: #fff; margin-bottom: 8px; line-height: 1.4; } .cta-a .cta-s { font-family: 'Source Sans 3', sans-serif; font-size: 15px; color: rgba(255,255,255,.78); margin-bottom: 20px; line-height: 1.6; } .btn-white { display: inline-block; background: #fff; color: var(--green-dark); font-family: 'Source Sans 3', sans-serif; font-size: 15px; font-weight: 600; padding: 11px 22px; border-radius: 6px; text-decoration: none; transition: background 0.15s; } .btn-white:hover { background: #e8f4ee; }

.cta-b { border: 1.5px solid var(--green-border); background: #fff; border-radius: 10px; padding: 20px 22px 22px; margin: 24px 0; display: flex; flex-direction: column; gap: 10px; } .cta-b .cta-h { font-family: 'Source Sans 3', sans-serif; font-size: 16px; font-weight: 600; color: var(--text-primary); line-height: 1.4; } .cta-b .cta-s { font-family: 'Source Sans 3', sans-serif; font-size: 14px; color: var(--text-muted); line-height: 1.6; } .btn-green { display: inline-block; background: var(--green-dark); color: #fff; font-family: 'Source Sans 3', sans-serif; font-size: 14px; font-weight: 600; padding: 10px 20px; border-radius: 6px; text-decoration: none; align-self: flex-start; transition: background 0.15s; } .btn-green:hover { background: var(--green-mid); }

.cta-c { display: flex; align-items: flex-start; gap: 14px; background: var(--cream-dark); border: 1px solid var(--border-soft); border-radius: 8px; padding: 16px 20px; margin: 20px 0; text-decoration: none; transition: border-color 0.15s, background 0.15s; } .cta-c:hover { background: var(--green-light); border-color: var(--green-border); } .cta-c .cta-arrow { font-size: 20px; color: var(--green-mid); line-height: 1; flex-shrink: 0; margin-top: 2px; } .cta-c .rl-label { font-size: 15px; color: var(--green-mid); font-weight: 600; margin-bottom: 4px; font-family: 'Source Sans 3', sans-serif; } .cta-c .rl-desc { font-size: 14px; color: var(--text-muted); font-family: 'Source Sans 3', sans-serif; line-height: 1.5; }

@media (max-width: 580px) { .country-grid { grid-template-columns: 1fr; } .stat-strip { grid-template-columns: 1fr 1fr; } .cost-table { font-size: 13px; } .cost-table thead th, .cost-table tbody td { padding: 9px 10px; } } </style> </head> <body> <div class="page-wrap">

<span class="meta-tag">Medical Tourism · Cervical Cancer · India</span>

<h1>Why Women from Africa and South Asia Are Choosing India for Cervical Cancer Treatment</h1>

<p class="deck">Brachytherapy. Robotic surgery. Pembrolizumab. Bevacizumab. These are the treatments that cure and control cervical cancer. They are unavailable or unaffordable for most women in sub-Saharan Africa and much of South Asia. India offers all of them — at costs that families can actually meet.</p>

<div class="illustration-wrap"> <svg viewBox="0 0 700 200" xmlns="http://www.w3.org/2000/svg" role="img" aria-label="Illustrated diagram showing patient journey routes from source countries to India for cervical cancer treatment. Origin markers on the left show Nigeria, Ghana, Kenya, Tanzania, Zambia, Bangladesh, and Nepal as labelled dots with curved flight-path lines connecting to a central India destination marker highlighted in green. The India marker is labelled with the four partner hospitals: Apollo, Fortis, Medanta, and Tata Memorial. A savings badge in the lower right shows up to 90% savings versus US treatment costs. The diagram conveys that patients travel from across sub-Saharan Africa and South Asia to receive cervical cancer treatment in India."> <defs> <linearGradient id="bgCC" x1="0" y1="0" x2="1" y2="1"> <stop offset="0%" stop-color="#EDE9DF"/> <stop offset="100%" stop-color="#E4DFCF"/> </linearGradient> <marker id="arrC" viewBox="0 0 10 10" refX="8" refY="5" markerWidth="5" markerHeight="5" orient="auto-start-reverse"> <path d="M2 1L8 5L2 9" fill="none" stroke="#C2DFCC" stroke-width="1.5" stroke-linecap="round" stroke-linejoin="round"/> </marker> </defs> <rect width="700" height="200" fill="url(#bgCC)"/>

<text x="130" y="22" text-anchor="middle" font-family="'Source Sans 3',sans-serif" font-size="11" font-weight="600" fill="#6B6860" letter-spacing="0.07em">PATIENTS TRAVELLING FROM</text> <text x="560" y="22" text-anchor="middle" font-family="'Source Sans 3',sans-serif" font-size="11" font-weight="600" fill="#1B5E3B" letter-spacing="0.07em">TREATMENT IN INDIA</text> <line x1="310" y1="12" x2="310" y2="188" stroke="#DDD9CF" stroke-width="1" stroke-dasharray="4 3"/>

<circle cx="68" cy="55" r="5" fill="#B07A15" opacity="0.8"/> <text x="80" y="59" font-family="'Source Sans 3',sans-serif" font-size="12" fill="#2E2E2A">Nigeria</text> <circle cx="80" cy="82" r="5" fill="#B07A15" opacity="0.8"/> <text x="92" y="86" font-family="'Source Sans 3',sans-serif" font-size="12" fill="#2E2E2A">Ghana</text> <circle cx="105" cy="110" r="5" fill="#B07A15" opacity="0.8"/> <text x="117" y="114" font-family="'Source Sans 3',sans-serif" font-size="12" fill="#2E2E2A">Kenya</text> <circle cx="78" cy="138" r="5" fill="#B07A15" opacity="0.8"/> <text x="90" y="142" font-family="'Source Sans 3',sans-serif" font-size="12" fill="#2E2E2A">Tanzania</text> <circle cx="60" cy="164" r="5" fill="#B07A15" opacity="0.8"/> <text x="72" y="168" font-family="'Source Sans 3',sans-serif" font-size="12" fill="#2E2E2A">Zambia</text>

<circle cx="218" cy="58" r="5" fill="#9A4020" opacity="0.8"/> <text x="230" y="62" font-family="'Source Sans 3',sans-serif" font-size="12" fill="#2E2E2A">Bangladesh</text> <circle cx="215" cy="90" r="5" fill="#9A4020" opacity="0.8"/> <text x="227" y="94" font-family="'Source Sans 3',sans-serif" font-size="12" fill="#2E2E2A">Nepal</text> <circle cx="225" cy="120" r="5" fill="#9A4020" opacity="0.8"/> <text x="237" y="124" font-family="'Source Sans 3',sans-serif" font-size="12" fill="#2E2E2A">Sri Lanka</text> <circle cx="210" cy="150" r="5" fill="#9A4020" opacity="0.8"/> <text x="222" y="154" font-family="'Source Sans 3',sans-serif" font-size="12" fill="#2E2E2A">Pakistan</text>

<path d="M73 55 Q330 20 490 100" fill="none" stroke="#C2DFCC" stroke-width="1.2" marker-end="url(#arrC)" opacity="0.8"/> <path d="M85 80 Q330 45 490 100" fill="none" stroke="#C2DFCC" stroke-width="1.2" marker-end="url(#arrC)" opacity="0.7"/> <path d="M110 108 Q340 75 490 100" fill="none" stroke="#C2DFCC" stroke-width="1.2" marker-end="url(#arrC)" opacity="0.7"/> <path d="M83 136 Q340 120 490 100" fill="none" stroke="#C2DFCC" stroke-width="1.2" marker-end="url(#arrC)" opacity="0.6"/> <path d="M65 162 Q340 150 490 100" fill="none" stroke="#C2DFCC" stroke-width="1.2" marker-end="url(#arrC)" opacity="0.6"/> <path d="M240 58 Q380 30 490 100" fill="none" stroke="#C2DFCC" stroke-width="1.2" marker-end="url(#arrC)" opacity="0.8"/> <path d="M237 88 Q390 65 490 100" fill="none" stroke="#C2DFCC" stroke-width="1.2" marker-end="url(#arrC)" opacity="0.7"/> <path d="M247 118 Q400 110 490 100" fill="none" stroke="#C2DFCC" stroke-width="1.2" marker-end="url(#arrC)" opacity="0.7"/> <path d="M232 148 Q400 140 490 100" fill="none" stroke="#C2DFCC" stroke-width="1.2" marker-end="url(#arrC)" opacity="0.6"/>

<circle cx="490" cy="100" r="22" fill="#1B5E3B" opacity="0.12"/> <circle cx="490" cy="100" r="14" fill="#1B5E3B" opacity="0.25"/> <circle cx="490" cy="100" r="7" fill="#1B5E3B"/> <text x="490" y="136" text-anchor="middle" font-family="'Source Sans 3',sans-serif" font-size="13" font-weight="600" fill="#1B5E3B">India</text> <text x="530" y="58" font-family="'Source Sans 3',sans-serif" font-size="11" fill="#2D7A52">Apollo · Fortis</text> <text x="530" y="72" font-family="'Source Sans 3',sans-serif" font-size="11" fill="#2D7A52">Medanta · Tata Memorial</text>

<rect x="530" y="88" width="148" height="52" rx="8" fill="#EAF4EE" stroke="#C2DFCC" stroke-width="1"/> <text x="604" y="110" text-anchor="middle" font-family="'Source Sans 3',sans-serif" font-size="22" font-weight="600" fill="#1B5E3B">Up to 90%</text> <text x="604" y="128" text-anchor="middle" font-family="'Source Sans 3',sans-serif" font-size="11" fill="#6B6860">savings vs US costs</text> </svg> <p class="img-caption">Patients from <a href="https://gafhealthcare.in/nigeria/treatment-in-india" style="color:var(--text-muted);">Nigeria</a>, <a href="https://gafhealthcare.in/ghana/treatment-in-india" style="color:var(--text-muted);">Ghana</a>, <a href="https://gafhealthcare.in/kenya/treatment-in-india" style="color:var(--text-muted);">Kenya</a>, <a href="https://gafhealthcare.in/tanzania/treatment-in-india" style="color:var(--text-muted);">Tanzania</a>, <a href="https://gafhealthcare.in/zambia/treatment-in-india" style="color:var(--text-muted);">Zambia</a>, and <a href="https://gafhealthcare.in/bangladesh/treatment-in-india" style="color:var(--text-muted);">Bangladesh</a> are among the largest groups seeking cervical cancer treatment in India. The combination of internationally trained oncology teams, current-generation drugs, brachytherapy capability, and costs that are 80–90% lower than the US makes India the most viable option for the majority of international patients.</p> </div>

<div class="toc-box"> <div class="toc-label">What's in this guide</div> <ol> <li><a href="#why-home-isnt-enough">Why treatment at home is not always an option</a></li> <li><a href="#the-brachytherapy-gap">The brachytherapy gap — the treatment most women cannot access</a></li> <li><a href="#why-india">Six reasons India has become the answer</a></li> <li><a href="#cost">What cervical cancer treatment costs in India</a></li> <li><a href="#who-is-coming">Which countries are sending the most patients — and why</a></li> <li><a href="#hospitals">The four hospitals GAF Healthcare recommends</a></li> <li><a href="#how-it-works">How the process works from your country to discharge</a></li> </ol> </div>

<h2 id="why-home-isnt-enough">Why treatment at home is not always an option</h2>

<p>Cervical cancer is one of the most treatable cancers in oncology — when the right treatment is available. Stage II and III cervical cancer, treated with concurrent chemoradiation and brachytherapy, carries five-year survival rates of 50–75%. That is not a poor prognosis. It is a genuinely good one — if the treatment is delivered correctly.</p>

<p>The problem is not the cancer. It is the infrastructure.</p>

<p>Brachytherapy — internal radiation delivered directly to the cervical tumour — is essential for curative treatment of stage II and III cervical cancer. Without it, external beam radiation alone achieves significantly worse outcomes. And brachytherapy is simply not available in most public hospitals across sub-Saharan Africa.</p>

<div class="quick-box"> <div class="qa-label">Quick answer</div> <div class="qa-question">Why do women with cervical cancer travel to India specifically?</div> <div class="qa-answer">Because India offers the complete treatment — <strong>concurrent chemoradiation, high-dose-rate brachytherapy, robotic surgery, bevacizumab biosimilars, and pembrolizumab</strong> — at costs that are 80–90% lower than the US or UK. For most women from sub-Saharan Africa or South Asia, the alternative to India is not a Western cancer centre. It is incomplete treatment at home — or no treatment at all.</div> </div>

<p>The World Health Organisation estimates that fewer than 30% of African cancer patients who need radiation therapy can access it. For cervical cancer specifically — the most common female cancer in sub-Saharan Africa — this gap is catastrophic.</p>

<p>India closes it. Not as a compromise, but as a genuine clinical solution — with the same treatment, the same protocols, and the same drugs used at leading cancer centres in Europe and the United States.</p>

<div class="callout-red"> <div class="callout-label">The scale of the problem in sub-Saharan Africa</div> <p>Cervical cancer is the leading cause of cancer death among women in sub-Saharan Africa. The region has some of the highest cervical cancer incidence rates in the world — driven by high HPV prevalence, limited screening, and late-stage diagnosis. Fewer than 10 countries in sub-Saharan Africa have functional brachytherapy services. A woman in <a href="https://gafhealthcare.in/nigeria/treatment-in-india" style="color:var(--red-accent);text-decoration:underline;text-decoration-color:#E8BABA;">Nigeria</a>, <a href="https://gafhealthcare.in/ghana/treatment-in-india" style="color:var(--red-accent);text-decoration:underline;text-decoration-color:#E8BABA;">Ghana</a>, <a href="https://gafhealthcare.in/zambia/treatment-in-india" style="color:var(--red-accent);text-decoration:underline;text-decoration-color:#E8BABA;">Zambia</a>, or <a href="https://gafhealthcare.in/tanzania/treatment-in-india" style="color:var(--red-accent);text-decoration:underline;text-decoration-color:#E8BABA;">Tanzania</a> with stage IIB cervical cancer is not facing a treatment choice. She is facing a treatment availability crisis. India is the realistic answer for this patient — not the ideal answer in a perfect world, but the practical answer in the world that exists.</p> </div>

<div class="cta-b"> <p class="cta-h">Diagnosed with cervical cancer and unsure what is available near you?</p> <p class="cta-s">Share your diagnosis with our team. We will tell you honestly whether what you need is available locally — and whether India is the right next step. At no charge, within 24 hours.</p> <a href="https://gafhealthcare.in/contact" class="btn-green">Get a Free Assessment →</a> </div>

<h2 id="the-brachytherapy-gap">The brachytherapy gap — the treatment most women cannot access</h2>

<p>Brachytherapy deserves its own section — because it is the single most important treatment access gap for cervical cancer patients globally, and the one India most decisively addresses.</p>

<p>High-dose-rate (HDR) brachytherapy involves placing a small radiation source directly inside the cervix or vagina — delivering a precisely targeted dose of radiation to the tumour from the inside. External beam radiation alone cannot achieve equivalent tumour coverage without unacceptable dose to the surrounding bladder and rectum.</p>

<p>The GEC-ESTRO guidelines — the international standard for cervical cancer brachytherapy — specify image-guided adaptive brachytherapy (IGABT) using MRI or CT planning for each brachytherapy fraction. This is the technique that produces the best tumour control with the least toxicity.</p>

<p>All four GAF Healthcare partner hospitals in India deliver IGABT to this standard.</p>

<div class="callout-amber"> <div class="callout-label">What happens when brachytherapy is not available</div> <p>Patients who receive external beam radiation alone — without brachytherapy — for stage II–III cervical cancer have significantly worse local control and survival outcomes. This is not a minor difference. Multiple studies have confirmed that omitting brachytherapy is associated with substantially higher local recurrence rates and lower five-year survival. For women in countries where brachytherapy is unavailable, this is the clinical reality. Travelling to India for the complete treatment is not over-treatment. It is the correct treatment.</p> </div>

<p class="impact">"The machine that delivers brachytherapy costs over a million dollars. India has it in every major cancer centre. Most of Africa does not have it at all. That single fact explains most of why our cervical cancer patients travel."</p>

<h2 id="why-india">Six reasons India has become the answer</h2>

<div class="reason-list"> <div class="reason-card"> <div class="reason-number">01</div> <div class="reason-body"> <h4>Complete treatment — not a reduced version</h4> <p>India's top centres deliver the full cervical cancer treatment protocol: concurrent chemoradiation with weekly cisplatin, image-guided external beam radiation, high-dose-rate brachytherapy, and systemic therapy where indicated. The protocol follows NCCN and FIGO guidelines — the same frameworks used at MD Anderson and the Royal Marsden. <strong>Nothing is omitted because of cost or infrastructure.</strong></p> </div> </div> <div class="reason-card"> <div class="reason-number">02</div> <div class="reason-body"> <h4>Brachytherapy available as standard</h4> <p>HDR brachytherapy with MRI-based planning is available at <a href="https://gafhealthcare.in/hospitals/apollo-hospitals-new-delhi" style="color:var(--green-mid);text-decoration:underline;text-decoration-color:var(--green-border);">Apollo</a>, <a href="https://gafhealthcare.in/hospitals/fortis-memorial-research-institute-gurgaon" style="color:var(--green-mid);text-decoration:underline;text-decoration-color:var(--green-border);">Fortis Memorial</a>, <a href="https://gafhealthcare.in/hospitals/medanta-the-medicity-gurgaon" style="color:var(--green-mid);text-decoration:underline;text-decoration-color:var(--green-border);">Medanta</a>, and <a href="https://gafhealthcare.in/hospitals/tata-memorial-hospital-mumbai" style="color:var(--green-mid);text-decoration:underline;text-decoration-color:var(--green-border);">Tata Memorial</a>. Tata Memorial alone performs more brachytherapy procedures for cervical cancer annually than most European countries combined. The radiation oncologists who lead these programmes trained at international institutions and publish in peer-reviewed oncology journals.</p> </div> </div> <div class="reason-card"> <div class="reason-number">03</div> <div class="reason-body"> <h4>Robotic surgery for early-stage disease</h4> <p>Women with stage I cervical cancer who need radical hysterectomy have access to robotic-assisted surgery at India's top centres — shorter hospital stays, less blood loss, faster recovery, and equivalent oncological outcomes. Fertility-sparing radical trachelectomy for young women with stage IB1 disease is also available. <strong>Robotic radical hysterectomy in India costs $5,000–$10,000</strong>, versus $40,000–$80,000 in the United States.</p> </div> </div> <div class="reason-card"> <div class="reason-number">04</div> <div class="reason-body"> <h4>Bevacizumab biosimilars at accessible cost</h4> <p>Bevacizumab — added to platinum-based chemotherapy for recurrent and metastatic cervical cancer — improves overall survival meaningfully but costs $4,000–$8,000 per cycle in the United States. In India, bevacizumab biosimilars are available at <strong>$200–$500 per cycle</strong>. For women with advanced cervical cancer from low-income countries, India is often the only realistic source of this drug.</p> </div> </div> <div class="reason-card"> <div class="reason-number">05</div> <div class="reason-body"> <h4>Pembrolizumab for eligible patients</h4> <p>The KEYNOTE-826 trial established pembrolizumab combined with chemotherapy as a first-line standard for PD-L1-positive persistent, recurrent, or metastatic cervical cancer. In India, pembrolizumab costs <strong>$1,200–$2,200 per cycle</strong>, compared to $10,000–$14,000 in the United States. India's partner hospitals test PD-L1 status as part of the workup for eligible patients and administer pembrolizumab where indicated.</p> </div> </div> <div class="reason-card"> <div class="reason-number">06</div> <div class="reason-body"> <h4>Fast medical visa — no waiting list</h4> <p>India issues medical visas for most African and South Asian nationalities within five to ten working days — covering the patient and up to two accompanying family members. There are no waiting lists for treatment appointments. Most patients begin their staging workup within 48 hours of arrival. <strong>For cervical cancer, which progresses, speed matters clinically.</strong> India's system is built for it.</p> </div> </div> </div>

<div class="cta-a"> <p class="cta-h">Ready to find out if India is right for your diagnosis?</p> <p class="cta-s">Share your biopsy report and staging details. Our medical team will review your case, recommend the right hospital, and give you an itemised cost estimate — at no charge, within 24 hours.</p> <a href="https://gafhealthcare.in/contact" class="btn-white">Get My Free Treatment Plan →</a> </div>

<h2 id="cost">What cervical cancer treatment costs in India</h2>

<p>These figures are based on GAF Healthcare's hospital network pricing as of 2025–2026. They are all-in costs — treatment, hospital stay, drugs, and procedures — not the procedure fee alone.</p>

<table class="cost-table"> <thead> <tr> <th>Treatment</th> <th>USA</th> <th>UK</th> <th class="india-head">India ✦</th> </tr> </thead> <tbody> <tr> <td>Full staging workup (MRI + CT + PET-CT)</td> <td>$8,000–$14,000</td> <td>£4,000–£7,000</td> <td class="saving">$600–$1,200</td> </tr> <tr class="highlight"> <td>Radical hysterectomy (robotic, stage I)</td> <td>$40,000–$80,000</td> <td>£18,000–£40,000</td> <td class="saving">$5,000–$10,000</td> </tr> <tr> <td>Full chemoradiation course (5–6 weeks EBRT + weekly cisplatin)</td> <td>$50,000–$120,000</td> <td>£22,000–£55,000</td> <td class="saving">$5,000–$10,000</td> </tr> <tr class="highlight"> <td>HDR brachytherapy course (full, with planning)</td> <td>$15,000–$35,000</td> <td>£8,000–£18,000</td> <td class="saving">$2,000–$4,500</td> </tr> <tr> <td>Complete chemoradiation + brachytherapy (stage II–III)</td> <td>$80,000–$180,000</td> <td>£35,000–£80,000</td> <td class="saving">$8,000–$18,000</td> </tr> <tr class="highlight"> <td>Bevacizumab biosimilar (per cycle)</td> <td>$4,000–$8,000</td> <td>£2,000–£4,500</td> <td class="saving">$200–$500</td> </tr> <tr> <td>Pembrolizumab (per cycle)</td> <td>$10,000–$14,000</td> <td>£5,000–£8,000</td> <td class="saving">$1,200–$2,200</td> </tr> <tr class="highlight"> <td>Cisplatin + paclitaxel (per cycle, stage IV)</td> <td>$3,000–$8,000</td> <td>£1,500–£4,000</td> <td class="saving">$250–$700</td> </tr> </tbody> </table> <p class="sources-line">✦ India figures from GAF Healthcare hospital network, 2025–2026. US: FAIR Health. UK: NHS reference costs and private sector benchmarks.</p>

<div class="stat-strip"> <div class="stat-cell"><div class="stat-label">Average saving vs USA</div><div class="stat-val">~88%</div></div> <div class="stat-cell"><div class="stat-label">Average saving vs UK</div><div class="stat-val">~80%</div></div> <div class="stat-cell"><div class="stat-label">Brachytherapy India vs USA</div><div class="stat-val">~87% less</div></div> <div class="stat-cell"><div class="stat-label">Visa processing time</div><div class="stat-val">5–10 days</div></div> </div>

<div class="callout-green"> <div class="callout-label">What GAF Healthcare cost estimates include</div> <p>Every cost estimate we provide covers the full treatment episode — radiation planning, EBRT sessions, brachytherapy fractions, cisplatin infusions, hospital stay during brachytherapy, oncology consultations, and discharge medications. For surgical cases, it includes the procedure, anaesthesia, hospital stay, and pathology. There are no hidden facility fees or unbundled billing surprises. If additional procedures are identified, they are quoted separately before proceeding.</p> </div>

<h2 id="who-is-coming">Which countries are sending the most patients — and why</h2>

<p>GAF Healthcare works with cervical cancer patients from over 30 countries. These are the regions we see most consistently — and the specific reasons each finds India particularly compelling.</p>

<div class="country-grid"> <div class="country-card"> <div class="country-name"><span class="country-flag">🇳🇬</span> <a href="https://gafhealthcare.in/nigeria/treatment-in-india" style="color:var(--text-primary);text-decoration:none;border-bottom:1px solid var(--green-border);">Nigeria</a></div> <ul> <li><strong>Highest cervical cancer rate</strong> in West Africa</li> <li>Brachytherapy not reliably available publicly</li> <li>Bevacizumab and pembrolizumab inaccessible locally</li> <li>India visa granted in 5–7 days</li> </ul> </div> <div class="country-card"> <div class="country-name"><span class="country-flag">🇰🇪</span> <a href="https://gafhealthcare.in/kenya/treatment-in-india" style="color:var(--text-primary);text-decoration:none;border-bottom:1px solid var(--green-border);">Kenya</a></div> <ul> <li>Kenyatta National Hospital has long waiting lists</li> <li><strong>Brachytherapy capacity severely limited</strong></li> <li>Systemic therapy access patchy outside Nairobi</li> <li>Direct flights to Delhi and Mumbai available</li> </ul> </div> <div class="country-card"> <div class="country-name"><span class="country-flag">🇬🇭</span> <a href="https://gafhealthcare.in/ghana/treatment-in-india" style="color:var(--text-primary);text-decoration:none;border-bottom:1px solid var(--green-border);">Ghana</a></div> <ul> <li>Cervical cancer <strong>leading cause of cancer death</strong> in women</li> <li>Radiation therapy capacity critically limited</li> <li>No reliable brachytherapy nationally</li> <li>India costs achievable with family pooling</li> </ul> </div> <div class="country-card"> <div class="country-name"><span class="country-flag">🇹🇿</span> <a href="https://gafhealthcare.in/tanzania/treatment-in-india" style="color:var(--text-primary);text-decoration:none;border-bottom:1px solid var(--green-border);">Tanzania</a></div> <ul> <li>Ocean Road Cancer Institute overwhelmed with demand</li> <li><strong>Brachytherapy waiting lists extremely long</strong></li> <li>Stage III and IV patients often untreated locally</li> <li>GAF Healthcare established referral network</li> </ul> </div> <div class="country-card"> <div class="country-name"><span class="country-flag">🇿🇲</span> <a href="https://gafhealthcare.in/zambia/treatment-in-india" style="color:var(--text-primary);text-decoration:none;border-bottom:1px solid var(--green-border);">Zambia</a></div> <ul> <li>One of highest cervical cancer rates globally</li> <li><strong>Radiation services limited to Lusaka</strong></li> <li>Brachytherapy intermittently unavailable</li> <li>India visa processed within 6–9 days</li> </ul> </div> <div class="country-card"> <div class="country-name"><span class="country-flag">🇧🇩</span> <a href="https://gafhealthcare.in/bangladesh/treatment-in-india" style="color:var(--text-primary);text-decoration:none;border-bottom:1px solid var(--green-border);">Bangladesh</a></div> <ul> <li>Cervical cancer second most common female cancer</li> <li><strong>Brachytherapy available but quality variable</strong></li> <li>India costs affordable on Bangladeshi income</li> <li>Cultural familiarity and 2-hour direct flight</li> </ul> </div> </div>

<p class="impact">"I was told in Accra that brachytherapy was not available and I would need to wait months for external radiation alone. In India, I had my full treatment — chemoradiation and brachytherapy — completed within eight weeks of arriving."</p>

<a href="https://gafhealthcare.in/treatments/cervical-cancer-treatment" class="cta-c"> <div class="cta-arrow">→</div> <div> <div class="rl-label">Full Cervical Cancer Treatment Guide — GAF Healthcare</div> <div class="rl-desc">Complete guide to cervical cancer treatment in India — surgery, chemoradiation, brachytherapy, immunotherapy, costs, and how to arrange care from your country.</div> </div> </a>

<h2 id="hospitals">The four hospitals GAF Healthcare recommends</h2>

<p>These are the centres we direct our cervical cancer patients to most consistently — assessed for radiation infrastructure, surgical volume, brachytherapy capability, drug formulary, and international patient support.</p>

<div class="hospital-grid"> <div class="hospital-card"> <div class="hospital-rank">01</div> <div class="hospital-info"> <h4><a href="https://gafhealthcare.in/hospitals/tata-memorial-hospital-mumbai">Tata Memorial Hospital — Mumbai</a></h4> <p>India's foremost dedicated cancer centre and the <strong>highest-volume cervical cancer treatment institution in Asia</strong>. Tata Memorial's gynaecological oncology and radiation oncology teams have treated more cervical cancer patients annually than most national cancer systems in Europe. The brachytherapy programme — image-guided, MRI-planned, delivered to GEC-ESTRO standards — is among the most experienced in the world. First choice for stage II–IV disease and complex cases.</p> </div> </div> <div class="hospital-card"> <div class="hospital-rank">02</div> <div class="hospital-info"> <h4><a href="https://gafhealthcare.in/hospitals/apollo-hospitals-new-delhi">Apollo Hospitals — New Delhi</a></h4> <p>India's largest private cancer network with <strong>full gynaecological oncology capability</strong> — robotic radical hysterectomy, radical trachelectomy, HDR brachytherapy with CT/MRI planning, and a complete systemic therapy formulary. Apollo's international patient infrastructure is the strongest in India — multilingual coordinators, Arabic and Swahili support, and a dedicated gynaecological oncology tumour board. Best choice for early-stage surgical cases and patients wanting a private hospital environment.</p> </div> </div> <div class="hospital-card"> <div class="hospital-rank">03</div> <div class="hospital-info"> <h4><a href="https://gafhealthcare.in/hospitals/medanta-the-medicity-gurgaon">Medanta — The Medicity, Gurgaon</a></h4> <p>Strong gynaecological oncology programme with <strong>full brachytherapy and robotic surgery capability</strong>. Medanta has a well-established track record with patients from <a href="https://gafhealthcare.in/nigeria/treatment-in-india" style="color:var(--green-mid);text-decoration:underline;text-decoration-color:var(--green-border);">Nigeria</a>, <a href="https://gafhealthcare.in/kenya/treatment-in-india" style="color:var(--green-mid);text-decoration:underline;text-decoration-color:var(--green-border);">Kenya</a>, <a href="https://gafhealthcare.in/bangladesh/treatment-in-india" style="color:var(--green-mid);text-decoration:underline;text-decoration-color:var(--green-border);">Bangladesh</a>, and the Gulf. On-campus accommodation for patients undergoing the seven to eight week chemoradiation and brachytherapy course. 25 minutes from Delhi international airport.</p> </div> </div> <div class="hospital-card"> <div class="hospital-rank">04</div> <div class="hospital-info"> <h4><a href="https://gafhealthcare.in/hospitals/fortis-memorial-research-institute-gurgaon">Fortis Memorial Research Institute — Gurgaon</a></h4> <p>Consistently strong surgical outcomes and <strong>full radiation oncology infrastructure</strong> including HDR brachytherapy. Fortis Memorial's gynaecological oncology team holds weekly tumour board reviews. A strong choice for stage I surgical cases and patients requiring neoadjuvant chemotherapy before surgery. 30 minutes from Delhi international airport, with established relationships with patients from East Africa and the Gulf.</p> </div> </div> </div>

<h2 id="how-it-works">How the process works from your country to discharge</h2>

<p>The logistics are more manageable than they look from the outside. GAF Healthcare handles every step — so that by the time you arrive in India, your treatment plan is confirmed, your first appointment is scheduled, and your oncology team has already reviewed your case.</p>

<div class="timeline"> <div class="timeline-item"> <div class="timeline-left"> <div class="timeline-dot">1</div> <div class="timeline-line"></div> </div> <div class="timeline-content"> <h4>Submit your reports remotely — Day 1</h4> <p>Send your biopsy report, any imaging, and your diagnosis summary to GAF Healthcare. <strong>No travel required at this stage.</strong> Our medical team reviews your case and connects you with an Indian gynaecological oncologist within 24 hours.</p> </div> </div> <div class="timeline-item"> <div class="timeline-left"> <div class="timeline-dot">2</div> <div class="timeline-line"></div> </div> <div class="timeline-content"> <h4>Receive treatment plan and cost estimate — Day 2–4</h4> <p>We confirm your treatment pathway — surgery, chemoradiation, or combined — and send itemised cost estimates from two to three shortlisted hospitals. <strong>No hidden costs.</strong> You choose the hospital that suits you.</p> </div> </div> <div class="timeline-item"> <div class="timeline-left"> <div class="timeline-dot">3</div> <div class="timeline-line"></div> </div> <div class="timeline-content"> <h4>Apply for Indian medical visa — Week 1</h4> <p>GAF Healthcare provides the hospital invitation letter within 24 hours of hospital confirmation. India's medical visa covers you and up to two family members. <strong>Most nationalities receive approval within five to ten working days.</strong></p> </div> </div> <div class="timeline-item"> <div class="timeline-left"> <div class="timeline-dot">4</div> <div class="timeline-line"></div> </div> <div class="timeline-content"> <h4>Arrive and complete staging workup — Week 2–3</h4> <p>Airport transfer is arranged. The full staging workup — MRI pelvis, CT chest/abdomen, PET-CT — is completed within 48 hours of arrival. Treatment begins within one to two weeks of arrival. <strong>For chemoradiation patients, plan to be in India for seven to eight weeks.</strong></p> </div> </div> <div class="timeline-item"> <div class="timeline-left"> <div class="timeline-dot">5</div> <div class="timeline-line"></div> </div> <div class="timeline-content"> <h4>Complete treatment and return home — Week 9–10</h4> <p>You receive a complete discharge pack — treatment summary, radiation records, pathology, and a follow-up plan for your local doctor. GAF Healthcare follows up at 30 and 90 days post-discharge. <strong>Adjuvant systemic therapy can be continued at home</strong> with your local oncologist using our written treatment plan.</p> </div> </div> </div>

<div class="cta-b"> <p class="cta-h">How long would I need to be in India for cervical cancer treatment?</p> <p class="cta-s">For chemoradiation and brachytherapy (stage II–III): approximately seven to eight weeks. For surgical cases (stage I): two to three weeks. Share your stage and we will give you a specific timeline and cost estimate — at no charge.</p> <a href="https://gafhealthcare.in/contact" class="btn-green">Get My Timeline and Cost →</a> </div>

<div class="cta-a"> <p class="cta-h">Take the first step. It costs nothing and takes less than 24 hours.</p> <p class="cta-s">Share your diagnosis with GAF Healthcare. We will review your case, recommend the right hospital, give you transparent cost figures, and walk you through exactly what happens next — at no charge, no obligation.</p> <a href="https://gafhealthcare.in/contact" class="btn-white">Start My Free Consultation →</a> </div>

<a href="https://gafhealthcare.in/treatments/cervical-cancer-treatment" class="cta-c"> <div class="cta-arrow">→</div> <div> <div class="rl-label">Full Cervical Cancer Treatment Guide — GAF Healthcare</div> <div class="rl-desc">Surgery, chemoradiation, brachytherapy, immunotherapy, recovery timelines, and costs — everything international patients need to plan cervical cancer treatment in India.</div> </div> </a>

</div> </div> </body> </html>